ACIP Recommendations: Hepatitis B Vaccine

Advisory Committee on Immunization Practices (ACIP)

Key points

  • The Advisory Committee on Immunization Practices (ACIP) develops recommendations on how to use vaccines to control disease in the United States.
  • These recommendations become official ÐÇ¿ÕÓéÀÖ¹ÙÍø policy once adopted by ÐÇ¿ÕÓéÀÖ¹ÙÍø's Director.
  • Learn about current and historical ACIP recommendations for hepatitis B vaccine.

Published in Morbidity and Mortality Weekly Report (MMWR)

Voluntary nationwide recall‎

The vaccine manufacturer is initiating a of all remaining PreHevbrio® [Hepatitis B Vaccine (Recombinant); NDC 75052-001-10] due to restructuring of the company and discontinuing operations. Further distribution or use of any remaining PreHevbrio vaccine by healthcare providers or others should cease immediately. For more information, please visit Hepatitis B Vaccine Administration | Hepatitis B | ÐÇ¿ÕÓéÀÖ¹ÙÍø.

The Advisory Committee on Immunization Practices (ACIP) provides advice and guidance to the Director of the ÐÇ¿ÕÓéÀÖ¹ÙÍø regarding use of vaccines and related agents for control of vaccine-preventable diseases in the civilian population of the United States. Recommendations made by the ACIP are reviewed by the ÐÇ¿ÕÓéÀÖ¹ÙÍø Director and, if adopted, are published as official ÐÇ¿ÕÓéÀÖ¹ÙÍø/HHS recommendations in the Morbidity and Mortality Weekly Report (MMWR).